On June 23, 2021, Jerald Hammann announced that he had nominated 4 nominees for election to the Board of Adamis Pharmaceuticals Corporation to replace 4 incumbent directors. He believed the election of his nominees is an important step in the right direction for enhancing long-term value at the Company. Jerald Hammann also announced that it had recommended the shareholders to vote for shareholder proposals, asking the Company shareholders of Adamis approve (i) that the Board had been directed to make appropriate changes to the Company's governing documents and policies so that directors who fail to obtain majority votes in favor of their re-election, retaining a plurality vote standard for contested elections, may only serve as a holdover director until the earliest of 90 days after the voting results are determined, the date on which the board fills the seat as a vacancy, or the date of the director's resignation, (ii) that the Board had been directed to make appropriate changes to the Company's governing documents and policies so preferred shares are limited to a maximum of one vote per share, (iii) that the Board had been directed to make appropriate changes to the Company's governing documents and policies so so that the establishment of or material amendment of equity compensation arrangements requires the approval of a majority of the shareholders of the Company, at the Company’s annual shareholders meeting.